IPP Bureau
Fujifilm AI detects Covid-19 Pneumonia
By IPP Bureau - October 22, 2021
Fujifilm India recently introduced a “Covid-19 Pneumonia Image Analysis Program” that helps in diagnosing chest CT images that helps in findings of Covid-19 pneumonia
U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years
By IPP Bureau - October 22, 2021
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
MediBuddy records a steep increase in dermatology consultation amongst youngsters
By IPP Bureau - October 22, 2021
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Zydus announces update on a randomised trial of Saroglitazar Mg in NASH
By IPP Bureau - October 22, 2021
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22
By IPP Bureau - October 22, 2021
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22
By IPP Bureau - October 22, 2021
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
ISA celebrates October as stroke awareness month
By IPP Bureau - October 21, 2021
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Sage Therapeutics and Biogen plan to submit a New Drug Application (NDA) for zuranolone
By IPP Bureau - October 21, 2021
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Boehringer Ingelheim and partners to develop gene therapy for patients with cystic fibrosis
By IPP Bureau - October 21, 2021
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Global Heart Hub and Novartis partner to tackle ASCVD
By IPP Bureau - October 21, 2021
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
India approves LumiraDX’s Antigen test kit
By IPP Bureau - October 21, 2021
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
U.S. FDA gives green light to Moderna and J&J booster doses
By IPP Bureau - October 21, 2021
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Ivenix selects Eastman Tritan copolyester for its new infusion system
By IPP Bureau - October 21, 2021
Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections
Syngene revenue from operations up 17 per cent in Q2FY22
By IPP Bureau - October 21, 2021
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts
By IPP Bureau - October 21, 2021
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
